DSIP (Delta Sleep-Inducing Peptide) is a 9-amino acid neuropeptide isolated from rabbit cerebral blood during sleep. Nearly five decades of research spanning sleep optimization, chronic pain, stress hormone regulation, and addiction withdrawal has produced genuinely intriguing data — alongside significant replication challenges. Here's the full picture for 2026.
In 1977, Swiss researchers at the University of Basel isolated a tiny 9-amino acid peptide from the cerebral venous blood of sleeping rabbits. The blood drawn during electrically induced sleep contained a peptide that, when injected into recipient rabbits, reliably produced slow-wave delta activity on EEG. They called it DSIP: Delta Sleep-Inducing Peptide. [1]
What followed was nearly five decades of genuinely interesting — and genuinely contradictory — research. DSIP turned out to be far more than a sleep molecule. Studies found it modulating stress hormones (ACTH, cortisol), amplifying nocturnal growth hormone pulses, blunting chronic pain, helping manage opiate and alcohol withdrawal, and resynchronizing circadian rhythms. Some clinical studies showed beautiful results. Others couldn't replicate them.
In April 2026, DSIP (listed under its clinical name Emideltide) was included in the FDA's reclassification of research peptides, and it is on the agenda for the FDA's Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026 — which means it may soon be available through licensed 503A compounding pharmacies with a physician prescription. That regulatory context has renewed serious interest in what the evidence actually says. [8]
This guide covers DSIP's structure, mechanisms, the full scope of clinical evidence, regulatory status, dosing considerations from the research literature, and where to source research-grade DSIP.
What Is DSIP? Sequence, Structure, and Why It Crosses the Blood-Brain Barrier
DSIP is a nonapeptide — exactly 9 amino acids — with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). It has a molecular weight of approximately 849 Da, which would normally suggest poor CNS penetration. Yet radiolabeled studies have confirmed that DSIP crosses the blood-brain barrier (BBB) efficiently from peripheral circulation — a property that gives it access to hypothalamic and limbic structures relevant to sleep and stress regulation.
Unlike most neuropeptides, DSIP has never had a confirmed dedicated receptor identified. Researchers have proposed it may act through multiple receptor systems simultaneously — GABA-A, opioid, and somatostatin pathways have all been implicated — which partly explains why its effects are so wide-ranging and also why its mechanism remains contested. [6]
Key structural properties:
- Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE)
- Molecular weight: ~849 Da
- BBB penetration: Confirmed in radiolabeled studies
- Endogenous distribution: Hypothalamus, limbic system, pituitary, and peripheral organs including kidney, pancreas, and gut
- Plasma half-life: Minutes after IV administration
- Biological effect duration: Hours to days — far outlasting the plasma half-life
The mismatch between DSIP's short plasma half-life and its prolonged behavioral effects is one of the most puzzling aspects of the compound. Researchers have proposed that metabolically stable fragments of DSIP retain activity — but this hasn't been confirmed in human studies. [6]
How DSIP Works: Five Converging Mechanisms
DSIP doesn't work like a sedative. It doesn't force unconsciousness. Its sleep effects — when they occur — appear hours after administration, consistent with a compound that modulates the brain's own sleep-initiation circuitry rather than overriding it with sedation. This is likely why the published studies report no next-day grogginess, which is one of the most common complaints about conventional hypnotics.
Based on nearly 50 years of research across multiple labs, DSIP appears to act through several converging mechanisms: [2,6,7]
1. GABA-A Receptor Modulation
DSIP potentiates GABA-A receptor activity in a manner distinct from benzodiazepines. It enhances inhibitory tone without triggering the receptor downregulation and tolerance that characterize classical GABA-A sedatives. This may produce anxiolysis and sleep facilitation without the dependency pharmacology.
2. HPA Axis Normalization
DSIP consistently inhibits ACTH and cortisol secretion in subjects with elevated stress hormones. This is clinically significant: stress-induced HPA overdrive is a major driver of hyperarousal insomnia — the racing-mind, can't-switch-off pattern. By normalizing the HPA axis, DSIP may remove the neurochemical brake on sleep rather than pharmacologically imposing it. [4]
3. Growth Hormone Pulse Amplification
Studies document that DSIP stimulates episodic GH secretion, particularly amplifying the nocturnal GH pulse that normally accompanies slow-wave sleep. This positions DSIP at the intersection of sleep and recovery biology — GH released during deep sleep drives tissue repair, immune maintenance, and metabolic regulation.
4. Circadian Resynchronization
The 1986 Schneider-Helmert study found that DSIP had genuine chronobiotic properties — it shifted the timing of the circadian clock rather than simply sedating subjects. Phase-shifted patients (those with circadian misalignment, common in shift workers, jet-lagged travelers, and people with delayed sleep phase syndrome) showed significantly better responses than those with conventional sleep-onset insomnia. [4]
5. Opioid System Interaction
DSIP interacts with the endogenous opioid system — modulating opioid receptor sensitivity without being an opioid agonist itself. This interaction likely underlies its documented effects on chronic pain and addiction withdrawal, and differentiates it mechanistically from both opioids and non-opioid analgesics.
DSIP Human Sleep Studies: Reported Improvement Rates
Responder Rate Across Published DSIP Human Studies
All studies are small-N (6–15 subjects) and should not be considered definitive. No large Phase 3 RCTs for DSIP exist. Sources: PubMed 7028502, 6895513, 3582201, 6548970.
The Clinical Evidence: Four Key Studies
DSIP has been studied in humans since 1981. The evidence base is small by modern standards — no large Phase 3 RCTs exist — but what does exist is consistently intriguing:
Study 1 — Chronic insomnia: Six middle-aged chronic insomniacs received IV DSIP at 25 nmoles/kg (approx. 875–1,000 mcg for a 70 kg adult). Compared to placebo, DSIP produced longer total sleep time, higher sleep quality scores, and fewer nighttime awakenings. Critically, no daytime sedation was observed — distinguishing DSIP sharply from benzodiazepines and z-drugs. Five of six subjects (83%) responded. [2]
Study 2 — Healthy volunteers: In subjects without sleep disorders, DSIP increased total sleep time by 59% within a 130-minute window post-injection versus placebo. The effect onset (30–60 minutes) is consistent with BBB penetration kinetics. [3]
Study 3 — Phase-shifted insomnia: Patients with circadian misalignment received a 10-injection series of IV DSIP. Sleep timing normalized in 78% of responders, with effects persisting for months in several cases. This chronobiotic effect — resynchronizing the clock rather than merely sedating — is arguably the most clinically interesting finding in the entire DSIP literature. [4]
Study 4 — Chronic pain: Seven patients with migraine, vasomotor headaches, chronic tinnitus, and psychogenic pain received DSIP. Pain intensity scores decreased, sleep patterns normalized, and the authors also documented improvements in psychomotor performance and concentration — suggesting broad neuromodulatory effects beyond the sleep domain. [5]
The honest limitation: Most positive DSIP studies originate from a tight cluster of European researchers in the 1980s–1990s, used small samples (6–15 subjects), and have not been independently replicated in large randomized controlled trials. No DSIP receptor has been definitively identified. Whether DSIP is a primary sleep regulatory molecule or a peripheral neuromodulator whose sleep effects emerge secondarily from HPA normalization remains genuinely unclear. [6]
| Property | DSIP | Melatonin | Selank | Benzodiazepines |
|---|---|---|---|---|
| Mechanism | GABA-A, HPA axis, circadian | MT1/MT2 receptor agonist | GABAergic, enkephalins | GABA-A potentiation |
| Primary effect | Deep sleep, circadian resync | Sleep onset timing | Anxiolysis, mild sleep aid | Sedation, sleep onset |
| Daytime sedation | None reported | Occasional low-dose | Minimal | Yes (residual) |
| Dependency risk | None reported | None | None reported | Significant |
| Circadian resync | Yes (documented) | Yes (weaker) | No | No |
| Human trial data | Yes (small, 1980s) | Extensive RCTs | Yes (Russian studies) | Extensive RCTs |
| FDA status 2026 | 503A review (July 2026) | OTC supplement | Unscheduled research | Schedule IV/V Rx |
DSIP Dosing: What the Research Used
All published human studies administered DSIP intravenously. Current research practice extrapolates to subcutaneous (SC) injection based on DSIP's confirmed peripheral-to-CNS bioavailability, but no published human study has validated subcutaneous pharmacokinetics.
From the published literature (IV administration):
- Dose: 25 nmoles/kg ≈ 12.5 mcg/kg ≈ 875 mcg for a 70 kg adult
- Duration: Single dose to 10-dose series (given nightly or every other night)
- Timing: 30–60 minutes before desired sleep onset
- Reported side effects: None in published literature at these doses
Current research practice (SC, extrapolated — not validated in humans):
- Dose range: 100–500 mcg per administration
- Frequency: Nightly for 5–10 consecutive nights, then assessed
- Reconstitution: Bacteriostatic water, 1–2 mg/mL concentration
- Storage: Lyophilized powder stable at room temp; reconstituted: refrigerate, use within 14 days
These extrapolated dosing parameters have no established clinical validation. DSIP is a research compound without approved human dosing guidelines. VANDL Labs lists DSIP at $24.99–$39.99 with third-party COA.
Frequently Asked Questions About DSIP
Is DSIP the same as Emideltide?
Yes. Emideltide is the INN (International Nonproprietary Name) assigned to DSIP. The FDA's July 2026 advisory committee agenda lists it as "Emideltide (DSIP)." Both names refer to the same 9-amino acid neuropeptide with the sequence WAGGDASGE.
Can DSIP be taken orally?
Oral administration would destroy DSIP through gastric acid and proteolytic enzymes before significant absorption. All published human studies used intravenous administration. Subcutaneous injection is the current research standard. Some researchers have explored intranasal delivery (which bypasses the GI tract and can access the CNS via the olfactory route), but no published human data exists for intranasal DSIP.
Does DSIP cause dependence or tolerance?
No evidence of dependence, tolerance, or withdrawal syndrome has appeared in the published literature. This contrasts sharply with GABA-A sedatives (benzodiazepines, z-drugs) that produce tolerance with repeated use. DSIP appears to facilitate the brain's natural sleep architecture rather than suppressing it with exogenous sedation — which may explain the absence of tolerance in multi-week study protocols.
Why do DSIP's effects last longer than its plasma half-life?
This remains one of the most unresolved questions in DSIP pharmacology. After IV administration, DSIP has a plasma half-life of minutes — yet behavioral effects on sleep and pain have been reported to persist for days to months in some subjects. Proposed explanations include: persistent downstream effects on gene expression, formation of stable metabolic fragments that retain biological activity, or lasting changes in HPA axis set-points that outlast the peptide itself.
How is DSIP different from melatonin for sleep?
Melatonin primarily signals darkness to the suprachiasmatic nucleus via MT1/MT2 receptors, facilitating sleep-onset timing and circadian phase-shifting. DSIP appears to operate through different mechanisms: GABA-A potentiation, HPA axis normalization, and possibly direct effects on slow-wave sleep generation. The 1986 clinical study found DSIP particularly effective for phase-shifted insomnia — suggesting genuine chronobiotic properties that differ from melatonin's simpler clock-resetting signal.
Sources & References
- 1.Monnier VM, Schoenenberger GA. "Delta sleep-inducing peptide: isolation and characterization from rabbit cerebral venous blood during sleep" — Pflügers Archiv, 1977.View source
- 2.Schneider-Helmert D. "The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep" — Pharmacology, 1981.View source
- 3.Schneider-Helmert D, Schoenenberger GA. "Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior" — International Journal of Clinical Pharmacology, Therapy and Toxicology, 1981.View source
- 4.Schneider-Helmert D. "The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia" — European Neurology, 1986.View source
- 5.Khomulo PS, Shubaev VL, Nikitina GA. "Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study" — European Neurology, 1984.View source
- 6.Kovalzon VM, Strekalova TV. "Delta sleep-inducing peptide (DSIP): a still unresolved riddle" — Journal of Neurochemistry, 2006. DOI: 10.1111/j.1471-4159.2006.03664.x.View source
- 7.Yehuda S, Carasso RL. "DSIP — a tool for investigating the sleep onset mechanism: a review" — International Journal of Neuroscience, 1988.View source
- 8.FDA Pharmacy Compounding Advisory Committee. "PCAC July 23–24 2026: Emideltide (DSIP) under review for 503A compounding eligibility" — FDA.gov, 2026.View source